Long COVID and Post-Viral Syndromes

What the standard model gets wrong

The standard model approaches long COVID symptomatically. Cognitive symptoms go to neurology. Autonomic symptoms go to cardiology. GI symptoms go to gastroenterology. Each specialty addresses its piece. The result is a patient on six prescribers with partial improvement in each domain and no overall recovery.

The fragmentation is structural, not anyone's individual failing. The current diagnostic infrastructure does not have a category for a single bioenergetic injury that expresses in multiple systems. So the injury is split across specialties, and each specialty treats its local presentation.

The mechanistic literature is converging on a different account. Mitochondrial damage, NAD+ depletion, persistent low-grade inflammation, and endothelial dysfunction are consistently present and consistently correlate with severity. These are not separate problems. They are one problem with system-wide effects.

What the Host Capacity Model says about long COVID

SARS-CoV-2 damages mitochondria through several converging routes. Spike protein binds ACE2 on enterocytes, endothelial cells, and other ACE2-expressing tissues. The binding triggers ROS production and damages mitochondrial Complexes I, III, and IV. Viral 3CL protease cleaves PARP, which normally recycles NAD+, producing acute NAD+ depletion. The damage persists post-viral in patients who do not undergo bioenergetic recovery.

The downstream cascade is recognizable. Colonocytes lose oxidative capacity. The colonic oxygen gradient flattens. Dysbiosis sets in, often with a Klebsiella-dominant or sulfide-producer pattern. Endotoxemia rises. Chronic immune activation upregulates CD38, which further depletes NAD+ in every cell that has CD38. The cycle is self-sustaining.

Mast cells in this environment become trip-wired. The MCAS-like features of long COVID are downstream of the same upstream lesion that drives the GI and energetic features. Endothelial damage produces the dysautonomia. Neuronal mitochondrial under-resourcing produces the cognitive symptoms. One lesion, many faces.

This is why scattered symptomatic treatment plateaus. Antihistamines do not refuel mitochondria. Beta-blockers do not replete NAD+. Antimicrobials do not restore colonocyte oxidative capacity. Each helps its piece. None addresses the substrate.

Mechanistic treatment addresses the substrate first. NAD+ restoration, mitochondrial cofactor support, dysbiosis management, barrier restoration, and protection of bioenergetic recovery from re-exposure and overexertion. Symptom-layer treatment continues in parallel during the recovery window — it is not abandoned. It is sequenced under the upstream strategy.

Patterns I look for in cases like this

• Symptom onset within weeks to months of a confirmed COVID infection.
• Multi-system presentation that crosses GI, cognitive, autonomic, and energetic domains.
• Post-exertional malaise — symptoms worse 24 to 72 hours after exertion.
• A new dysbiotic pattern that did not exist pre-infection.
• Elevated lactate, low NAD+ on direct measurement.
• Mast cell features (flushing, food reactivity, dermographism) that are post-infection in origin.
• Cognitive symptoms that worsen later in the day, consistent with bioenergetic depletion.
• POTS or orthostatic intolerance that began after infection.
• Disproportionate response to small physical or cognitive demands.
• Persistent or recurrent stool SARS-CoV-2 RNA where antigenic persistence is suspected.

Tests I usually want to see

• Intracellular NAD+ panel — frequently below 300 μM in this population.
• Organic Acid Test — Krebs cycle intermediates, lactate to pyruvate ratio.
• Mitochondrial damage markers — serum lactate, 8-OHdG, carnitine.
• Inflammation panel — hs-CRP, IL-6, TNF-α.
• Barrier and endotoxin markers — zonulin, LPS, LBP, calprotectin.
• Shotgun metagenomics — Klebsiella, gram-negatives, butyrate producer status.
• D-dimer where micro-clotting is part of the picture.
• SARS-CoV-2 stool PCR where antigenic persistence is being evaluated.

Leverage points

Sustained NAD+ restoration is the foundation. IV NAD+ accelerates the timeline in resource-permitting cases. High-dose oral NMN over months is the broadly accessible equivalent. The pool must be repleted, not just spiked.

Dysbiosis treatment is non-negotiable. Post-viral dysbiosis perpetuates the inflammation that perpetuates the NAD+ consumption that prevents recovery. Treating the GI layer is treating the cycle.

Pacing matters mechanistically, not just symptomatically. Exertion in a bioenergetically under-resourced state produces real damage. Recovery requires protecting the system from demand it cannot meet, until it can meet it.

Where antigenic persistence is documented, that layer needs separate consideration. Working with a long-COVID specialist on the antiviral question is appropriate. The bioenergetic recovery strategy still applies and still benefits patients on antivirals.

Where this account may be wrong

The account is strongest for patients with mitochondrial features and GI involvement, who are the majority. Patients whose long-COVID picture is dominated by primary thromboinflammatory or autoimmune features may need additional frames beyond what this page describes. The bioenergetic strategy is necessary but may not be sufficient in those subgroups.

Frequently asked questions

Related reading

• The Host Capacity Model
• Post-COVID gut dysfunction protocol
• Mitochondrial dysfunction
• Refractory MCAS in the post-viral group
• Colonocyte bioenergetics